Dr Anant Ramaswamy speaks to ecancer in an online interview for the virtual ESMO GI 2020 meeting.

He describes the background and design of this phase II trial, which evaluated the efficacy of capecitabine-irinotecan (CAPIRI) versus irinotecan alone in patients with advanced gall bladder cancer, who have progressed on first-line chemotherapy.

Dr Ramaswamy explains the results achieved in this study, and notes that no significant differences were found between the two arms - with regards to overall survival, progression-free survival and quality of life.

He discusses the potential clinical implications of these results and the next steps for this study.